Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with L

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
4114 Q3 2021 LACTOSE MONOHYDRATE ORAL TABLET, FILM COATED, EXTENDED RELEASE 260.00 mg MDE Replacement
4114 Q4 2021 LACTOSE MONOHYDRATE ORAL TABLET, FILM COATED, EXTENDED RELEASE 520 mg MDE Replacement
4240 Q3 2021 LIGHT MINERAL OIL TOPICAL CREAM 20.00 %w/w MDE Replacement
4240 Q4 2021 LIGHT MINERAL OIL TOPICAL CREAM 456 mg MDE Replacement
4270 Q3 2021 LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) ORAL TABLET 80.00 mg MDE Replacement
4270 Q4 2021 LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) ORAL TABLET 369.6 mg MDE Replacement
4272 Q3 2021 LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) ORAL TABLET, DELAYED RELEASE 26.30 mg MDE Replacement
4272 Q4 2021 LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) ORAL TABLET, DELAYED RELEASE 84 mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English